Biocannovea

Biocannovea has been operating from its Vienna base since 2018, positioning itself as an early entrant in the Austrian longevity market. The clinic's primary focus is on HHO (Hemo-Hyper-Oxygenation) blood purification therapy, which combines hemoperfusion, hyperthermia, and oxygenation. This treatment is offered for a range of health optimization goals, making it a distinctive modality not widely available at other longevity clinics. The free initial health consultation lowers the barrier to entry, allowing prospective patients to explore whether the approach aligns with their health goals before committing financially. The HHO therapy represents an innovative approach, though the peer-reviewed clinical evidence specifically supporting longevity benefits is still developing. The diagnostic offering, centered on 44 blood values, is narrower than competitors who analyze hundreds or thousands of biomarkers, which limits the depth of baseline health assessment available. Independent patient reviews across major platforms are very limited, making it difficult to form a comprehensive external view of patient experiences. As the clinic continues to build its evidence base and expand its diagnostic capabilities, publishing clinical outcomes and patient testimonials would significantly strengthen its market positioning. For patients in Austria interested in exploring blood purification therapy, Biocannovea offers early-mover experience with this specific modality.